Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GY4H
|
|||
| Former ID |
DNCL001718
|
|||
| Drug Name |
Taberminogene vadenovec
|
|||
| Synonyms |
Trinam (TN)
Click to Show/Hide
|
|||
| Indication | Vascular restinosis [ICD-11: BE2Z; ICD-10: T82.858A] | Phase 3 | [1] | |
| Company |
Ark Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 3 (FLT-4) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Pathway Interaction Database | VEGF and VEGFR signaling network | |||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | |||
| WikiPathways | Signaling by VEGF | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00895479) Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence. U.S. National Institutes of Health. | |||
| REF 2 | Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.